The Survival Probability of Covid-19 Patients with Type 2 Diabetes Mellitus during Pandemic at Al Ihsan Hospital, West Java Province, Indonesia
DOI:
https://doi.org/10.3889/oamjms.2023.11266Keywords:
Type 2 diabetes mellitus, Corona virus disease 2019, Survival analysisAbstract
BACKGROUND: The high prevalence of diabetes mellitus (DM) in the population causes DM to become one of the most common comorbidities of coronavirus disease 2019 (COVID-19). Patients with diabetes have a higher risk of experiencing serious complications from COVID-19 and even death.
AIM: This study was aimed to determine the difference in survival probability of COVID-19 patients, based on their DM status and to determine the association between type 2 DM and COVID-19 mortality at Al Ihsan Hospital, West Java Province, Indonesia.
METHODS: The population of this retrospective cohort study were COVID-19 patients, aged ≥18 years and were treated at Al Ihsan Hospital, from March 2020 to December 31, 2021. Differences in survival probability were obtained from survival analysis with Kaplan–Meier. Cox Proportional Hazard regression was used to determine the association between type 2 DM and COVID-19 mortality.
RESULTS: Totally, 308 confirmed positive COVID-19 patients were recruited in this study. During the 21 days of observation, survival probability of COVID-19 patients with type 2 DM was significantly lower than those without type 2 DM (71.24% vs. 84.13% respectively, with p = 0.0056). There was a statistically significant association between type 2 DM and COVID-19 mortality after controlling for age, cough symptoms, acute respiratory distress syndrome, vaccination, chronic kidney disease, ventilator use, antiviral therapy, and the percentage of bed occupation rate COVID-19 isolation at admission. The adjusted hazard ratio showing association between type 2 DM and COVID-19 mortality in the final model of multivariate analysis was 2.68 (95% CI 1.24–5.73).
CONCLUSIONS: The survival probability of COVID-19 patients with type 2 DM was significantly lower than those without type 2 DM. COVID-19 patients with DM in Al Ihsan Hospital were almost 3 times more likely to be fatal as compared COVID-19 patients without DM.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-60. http://doi.org/10.23750/abm.v91i1.9397
PMid:32191675
World Health Organization. COVID-19 Weekly Epidemiological Update. 81st ed. Geneva: World Health Organization; 2022.
Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci U S A. 2020;117(26):14857-63. https://doi.org/10.1073/pnas.2009637117 DOI: https://doi.org/10.1073/pnas.2009637117
World Health Organization. Therapeutics and COVID-19; Living Guide Line. Geneva: World Health Organization; 2022.
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547. http://doi.org/10.1183/13993003.00547-2020 PMid:32217650 DOI: https://doi.org/10.1183/13993003.01227-2020
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. http://doi.org/10.1016/j.diabres.2019.107843 PMid:31518657 DOI: https://doi.org/10.1016/j.diabres.2019.107843
Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238-46. http://doi.org/10.1016/j.ajic.2020.06.213 PMid:32659414 DOI: https://doi.org/10.1016/j.ajic.2020.06.213
Kemenkes RI. Laporan Nasional Riset Kesehatan Dasar. Jakarta, Indonesia: Kemenkes RI; 2018.
RSUD Al Ihsan. Laporan 10 Besar Penyakit Co Morbiditas Covid Rawat Inap Tahun 2021; 2022.
Ali MM, Malik MR, Ahmed AY, Bashir AM, Mohamed A, Abdi A, et al. Survival analysis of all critically ill patients with COVID-19 admitted to the main hospital in Mogadishu, Somalia, 30 March-12 June 2020: Which interventions are proving effective in fragile states? Int J Infect Dis. 2022;114:202-9. https://doi.org/10.1016/j.ijid.2021.11.018 PMid:34781004 DOI: https://doi.org/10.1016/j.ijid.2021.11.018
Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: A two-center, retrospective study. Diabetes Care. 2020;43(7):1382-91. http://doi.org/10.2337/dc20-0598 PMid:32409504 DOI: https://doi.org/10.2337/dc20-0598
Liu Y, Lu R, Wang J, Cheng Q, Zhang R, Zhang S, et al. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. BMC Endocr Disord. 2021;21(1):56. http://doi.org/10.1186/s12902-021-00717-6 PMid:33771154 DOI: https://doi.org/10.1186/s12902-021-00717-6
De Souza CD, de Arruda Magalhães AJ, Lima AJ, Nunes DN, de Fátima Machado Soares É, de Castro Silva L, et al. Clinical manifestations and factors associated with mortality from COVID-19 in older adults: Retrospective population-based study with 9807 older Brazilian COVID-19 patients. Geriatr Gerontol Int. 2020;20(12):1177-81. http://doi.org/10.1111/ggi.14061 PMid:33111433 DOI: https://doi.org/10.1111/ggi.14061
Harbuwono DS, Handayani DO, Wahyuningsih ES, Supraptowati N, Ananda, Kurniawan F, et al. Impact of diabetes mellitus on COVID-19 clinical symptoms and mortality: Jakarta’s COVID-19 epidemiological registry. Prim Care Diabetes. 2022;16(1):65-8. http://doi.org/10.1016/j.pcd.2021.11.002 PMid:34857490 DOI: https://doi.org/10.1016/j.pcd.2021.11.002
Guo L, Shi Z, Zhang Y, Wang C, Do Vale Moreira NC, Zuo H, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta- analysis. Diabetes Res Clin Pract. 2020;166:108346. http://doi.org/10.1016/j.diabres.2020.108346 PMid:32710998 DOI: https://doi.org/10.1016/j.diabres.2020.108346
McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LA, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: A cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9(2):82-93. http://doi.org/10.1016/S2213-8587(20)30405-8 PMid:33357491 DOI: https://doi.org/10.1016/S2213-8587(20)30405-8
Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: A national cohort study in England, March-July 2020. Diabetes Care. 2021;44(1):50-7. http://doi.org/10.2337/dc20-1444 PMid:33097559 DOI: https://doi.org/10.2337/dc20-1444
Bradley SA, Banach M, Alvarado N, Smokovski I, Bhaskar SM. Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Diabetes. 2022;14(2):144-57. http://doi.org/10.1111/1753-0407.13243 PMid:34939735 DOI: https://doi.org/10.1111/1753-0407.13243
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMid:31986264 DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-10. http://doi.org/10.1016/j.dsx.2020.04.004 PMid:32298981 DOI: https://doi.org/10.1016/j.dsx.2020.04.004
Mason K, Hasan S, Darukhanavala A, Kutney K. COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes. J Clin Transl Endocrinol. 2021;26:100268. http://doi.org/10.1016/j.jcte.2021.100268 PMid:34722160 DOI: https://doi.org/10.1016/j.jcte.2021.100268
Kim JH, Park K, Lee SB, Kang S, Park JS, Ahn CW, et al. Relationship between natural killer cell activity and glucose control in patients with Type 2 diabetes and pre-diabetes. J Diabetes Investig. 2019;10(5):1223-8. http://doi.org/10.1111/jdi.13002 PMid:30618112 DOI: https://doi.org/10.1111/jdi.13002
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74. http://doi.org/10.1038/s41577-020-0311-8 PMid:32346093 DOI: https://doi.org/10.1038/s41577-020-0311-8
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30. http://doi.org/10.1038/s41574-020-00435-4 PMid:33188364 DOI: https://doi.org/10.1038/s41574-020-00435-4
Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021;385(26):2413-20. https://doi.org/10.1056/NEJMoa2115624 PMid:34879190 DOI: https://doi.org/10.1056/NEJMoa2115624
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Oka Septiriani, Mondastri Korib Sudaryo, Syahrizal Syarif, Citra Citra (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
